Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3229632
Max Phase: Preclinical
Molecular Formula: C45H69N11O12S2
Molecular Weight: 1020.25
Molecule Type: Small molecule
Associated Items:
ID: ALA3229632
Max Phase: Preclinical
Molecular Formula: C45H69N11O12S2
Molecular Weight: 1020.25
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CC(C)(C)SSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Standard InChI: InChI=1S/C45H69N11O12S2/c1-7-24(4)37-43(67)51-27(14-15-33(46)58)39(63)52-30(19-34(47)59)40(64)54-31(44(68)56-16-8-9-32(56)42(66)53-28(17-23(2)3)38(62)49-21-35(48)60)22-69-70-45(5,6)20-36(61)50-29(41(65)55-37)18-25-10-12-26(57)13-11-25/h10-13,23-24,27-32,37,57H,7-9,14-22H2,1-6H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,61)(H,51,67)(H,52,63)(H,53,66)(H,54,64)(H,55,65)/t24-,27-,28-,29-,30-,31-,32-,37-/m0/s1
Standard InChI Key: IZIWNJRAVSDMFB-VNHOCEMUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1020.25 | Molecular Weight (Monoisotopic): 1019.4569 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Lowbridge J, Manning M, Seto J, Haldar J, Sawyer WH.. (1979) Synthetic antagonists of in vivo responses by the rat uterus to oxytocin., 22 (5): [PMID:458806] [10.1021/jm00191a019] |
2. Hruby VJ, Deb KK, Yamamoto DM, Hadley ME, Chan WY.. (1979) [1-Penicillamine,2-leucine]oxytocin. Synthesis and pharmacological and conformational studies of a potent peptide hormone inhibitor., 22 (1): [PMID:423185] [10.1021/jm00187a002] |
3. Manning M, Lowbridge J, Seto J, Haldar J, Sawyer WH.. (1978) [1-Deaminopenicillamine,4-threonine]oxytocin, a potent inhibitor of oxytocin., 21 (2): [PMID:621712] [10.1021/jm00200a007] |
4. Bankowski K, Manning M, Haldar J, Sawyer WH.. (1978) Design of potent antagonists of the vasopressor response to arginine-vasopressin., 21 (9): [PMID:722751] [10.1021/jm00207a002] |
Source(1):